Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves Cyberonics' VNS (vagus nerve stimulation) anxiety trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given Cyberonics the go-ahead to begin a pilot study to investigate the use of its implantable NCP vagus nerve stimulation (VNS) device as a treatment for three of five types of anxiety disorders - obsessive-compulsive disorder, panic disorder and adult onset post-traumatic stress disorder. The device, which was approved by the agency for the treatment of epilepsy in 1997, will be assessed in up to 30 patients at four sites, says the Houston, Texas company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel